Skip to main content

Table 1 Therapy and outcome

From: Long-term follow-up of cytogenetically normal CEBPA-mutated AML

  All patients (N = 88) moCEBPA(N = 43) biCEBPA(N = 45) P
  N % N % N %  
Number of induction cycles        
1 29 33 16 37 13 30 0.41
2 59 67 27 63 32 71  
Induction therapy regimen        0.48
In study 76 86 36 84 40 89  
In analogy to study 12 14 7 16 5 11  
Allogeneic SCT 19 22 10 23 9 20 0.75
in 1.CR 7 8 3 7 4 9  
Primary refractory 4 5 3 7 1 2  
At relapse 8 9 4 9 4 9  
Early death until day 30 4 5 3 7 1 2 0.28
Early death until day 60 7 8 4 9 3 7 0.65
CR/CRi* 67 76 30 70 37 82 0.17
Median OS, 95% CI, years 3.0 (0.9-5.2) 1.7 (0.7-2.7) 9.6 (NA) 0.008
Median RFS, 95% CI, years 2.3 (1.0-3.7) 1.5 (0.4-2.5) 9.4 (NA) 0.021
  1. *62 patients have achieved a CR; 5 patients have achieved a CRi;
  2. Abbreviations: biCEBPA biallelic mutation in the CCAAT/enhancer-binding protein alpha, CR complete remission, CRi CR with incomplete revovery, moCEBPA monoallelic mutation in the CCAAT/enhancer-binding protein alpha, N number, NA not applicable, SCT stem cell transplantation.